Parkwood LLC Makes New $10.53 Million Investment in Danaher Co. (NYSE:DHR)

Parkwood LLC purchased a new stake in shares of Danaher Co. (NYSE:DHR) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 45,856 shares of the conglomerate’s stock, valued at approximately $10,526,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock worth $13,715,641,000 after buying an additional 315,912 shares during the last quarter. Geode Capital Management LLC raised its position in Danaher by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock valued at $3,056,996,000 after purchasing an additional 315,446 shares in the last quarter. Norges Bank bought a new stake in Danaher during the fourth quarter worth about $2,130,740,000. Bank of New York Mellon Corp boosted its holdings in shares of Danaher by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after purchasing an additional 441,012 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Danaher by 14.3% during the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock valued at $1,821,477,000 after purchasing an additional 992,594 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This represents a 51.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.10% of the stock is currently owned by insiders.

Danaher Stock Performance

Shares of NYSE DHR opened at $196.60 on Wednesday. The firm’s fifty day moving average is $197.83 and its two-hundred day moving average is $218.54. Danaher Co. has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a market cap of $140.70 billion, a P/E ratio of 37.23, a P/E/G ratio of 2.66 and a beta of 0.80. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. As a group, analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.65%. Danaher’s dividend payout ratio is currently 24.85%.

Wall Street Analyst Weigh In

Several analysts have weighed in on DHR shares. Wells Fargo & Company lowered their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. JPMorgan Chase & Co. reduced their price target on Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 22nd. UBS Group dropped their price objective on Danaher from $275.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. StockNews.com raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Monday. Finally, Jefferies Financial Group lowered their price objective on shares of Danaher from $260.00 to $230.00 and set a “buy” rating for the company in a research note on Tuesday, April 22nd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $264.40.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.